| Symbol | ALC |
|---|---|
| Name | ALCON INC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Ophthalmic Goods |
| Address | 6201 SOUTH FREEWAY, FORT WORTH, TX 76134 |
| Telephone | 817 293 0450 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001167379 |
| Description | Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. Additional info from NASDAQ: |
Alcon - Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Read moreAlcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Read moreAlcon - New Product Launches and Strong Commercial Execution Drive Alcons Second-Quarter 2026 Growth
Read moreNew Product Launches and Strong Commercial Execution Drive Alcons Second-Quarter 2026 Growth
Read moreNew Product Launches and Strong Commercial Execution Drive Alcons Second-Quarter 2026 Growth
Read moreAlgoma Central Corporation Reports Financial Results for the 2026 Second Quarter
Read moreAlgoma Central Corporation to Issue Second Quarter Financial Results on August 7, 2026
Read more